Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. - Wikidata - awgldk - TriplyDB

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

http://www.wikidata.org/entity/Q30573030

about

Optimal management of seizures associated with tuberous sclerosis complex: current and emerging options Strategies for treatment in Alexander disease Emerging pharmacotherapies for neurodevelopmental disorders Ribosomal Protein S6 Phosphorylation in the Nervous System: From Regulation to Function The neurology of mTOR Recent treatment advances and novel therapeutic approaches in epilepsy Harnessing the power of metabolism for seizure prevention: focus on dietary treatments The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment.Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin Potential for treatment of severe autism in tuberous sclerosis complex Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target Anti-epileptogenic clinical trial designs in epilepsy: issues and options Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex.Pathogenesis and new candidate treatments for infantile spasms and early life epileptic encephalopathies: A view from preclinical studies mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia.Spatiotemporal characterization of mTOR kinase activity following kainic acid induced status epilepticus and analysis of rat brain response to chronic rapamycin treatment Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury Hyperactive mTOR signals in the proopiomelanocortin-expressing hippocampal neurons cause age-dependent epilepsy and premature death in mice Diagnostic methods and treatment options for focal cortical dysplasia mTOR signaling in tumorigenesis Translational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics.Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease Mapping the spatio-temporal pattern of the mammalian target of rapamycin (mTOR) activation in temporal lobe epilepsy Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex Gene expression profiling of a hypoxic seizure model of epilepsy suggests a role for mTOR and Wnt signaling in epileptogenesis.Effect of Chronic Administration of Low Dose Rapamycin on Development and Immunity in Young Rats Upregulation of glutamate transporter GLT-1 by mTOR-Akt-NF-кB cascade in astrocytic oxygen-glucose deprivation The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy Behavioural phenotyping assays for mouse models of autism Prenatal rapamycin results in early and late behavioral abnormalities in wildtype C57BL/6 mice Hereditary genodermatoses with cancer predisposition Impaired astrocytic gap junction coupling and potassium buffering in a mouse model of tuberous sclerosis complex.Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of Tuberous Sclerosis Complex.Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy.Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.A pulse rapamycin therapy for infantile spasms and associated cognitive decline.The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex.Excessive activation of mTOR in postnatally generated granule cells is sufficient to cause epilepsy.Mammalian target of rapamycin complex 1 activation negatively regulates Polo-like kinase 2-mediated homeostatic compensation following neonatal seizures.Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder

P2860

Q22305852-7512CC8E-88E4-46EA-897D-16CF768CA634 Q24596794-3CC39A8E-D65A-4619-8B5F-AE6B557F20C1 Q24619170-8A92967A-98C5-4598-8DBE-CF1C2C153D35 Q26770762-BE8D4AE3-1894-47A7-A025-EBC2E4B22268 Q26824286-400A8A89-B1B7-4E55-90F2-47C0E3C289A0 Q26824512-EB74443C-EBDF-446E-89F8-6224137A271D Q26991869-DCF14D72-5EDF-403E-AB51-B9FC70209D5D Q26998975-AC0595FE-BB86-47F3-BCA3-BDCF2D4CB1A7 Q27015640-384C3AA7-0F85-4BFB-AA36-096C661F2447 Q27021739-C80C7744-7F0B-41D7-B884-4652079592A5 Q27024547-DC764317-B1DF-407D-8306-4020D90D9CC9 Q27027689-249C2BCF-F74F-4E57-B2AF-138CEB3FEE88 Q27308042-1E726149-A814-4F1A-8575-7A1176E8CE51 Q27308052-771CA5A7-C8F9-4824-98AB-26929D6AA290 Q27312412-4D42ECDB-D654-493D-92B6-A7FC55F00702 Q27318635-E9324AF9-D8B6-42BF-9021-D0FAFFAA9B8A Q27319659-B60A326B-D6B5-4F08-B3EF-8DDD4D6D452E Q27332424-D06D38DA-E037-452D-981A-5C7842811E40 Q28081144-2EF387E1-9C8E-4598-A076-4DAA90DB1CA2 Q28252695-EC175BA0-4CF0-4233-9C72-C2C69EC2200D Q28394524-D6B96D43-D9C8-4D6C-8E0E-AD7DC83BB50F Q28476810-2A9C107E-E4BB-45DC-88D0-992E90C9D23A Q28480776-7940ABBF-3584-4414-88E6-0F1C354EBB10 Q28486250-643D0607-E1A2-4A98-9A6B-CE92F16FED2F Q28533881-E4F4686A-6DEE-43E6-8785-3AD15EA60B24 Q28547057-FDB1E5A5-786A-41D9-9640-07FE7B8FC4E4 Q28576235-6139B657-790B-4CE0-9470-D55119FC39FF Q28579751-1C514A77-5A6A-42AE-8917-D6AA1AE2E213 Q29618414-B068FA91-64B7-446D-8318-7E48BCA6E977 Q30444988-82EB0A5E-4593-4E23-9542-D1DF75A3526B Q30470596-E4120E57-B61F-44F6-AEB9-D4B4AE45DC88 Q30491063-5292FB46-148D-46FE-B724-1061262A94F4 Q30493205-D8E7CE66-A261-4F14-B7D2-655F8A07F195 Q30496223-901F1102-0F10-42C1-AF4D-E8C04397D573 Q30497818-4509876A-3D05-4179-B58A-0C76FEFD7E64 Q30501073-30EE18BD-F5C3-4AF1-A2C3-C4FB8023C0C6 Q30518266-9E33D553-EAF3-4CA5-9E8F-2EB588CED936 Q30525675-351DFBE8-C605-4BEA-8DCD-EDB1F7DED791 Q30538200-92B01E3D-9E0D-45DF-AE4E-1F4D886E5F71 Q30541746-3CBDA850-0D9B-4BDA-A906-5EB91A894974

P2860

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

http://www.wikidata.org/entity/Q30573030

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

@ast

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

@en

type

label

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

@ast

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

@en

prefLabel

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

@ast

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

@en

P1433

Q30573030-0FB5AE38-35F6-4451-8333-75E9495075CD

P1476

Q30573030-A6B2E64C-D6FE-47BE-93B1-EDE3AE69CBEB

P2093

Q30573030-676BE3AE-E0E5-48C5-883A-35FA95DDC2E2

Q30573030-72E11C3D-126C-4234-B7B9-B96DC5D24FED

Q30573030-BF11B3EA-E12A-471A-9003-C8BF3C7CB1EF

P2860

Q30573030-02BCFA18-0F7C-4776-A88F-B84386BA4AE1

Q30573030-0383E4D1-25DD-458E-B98A-488ACD023802

Q30573030-118B7F34-50F9-495E-8C64-27D0619A5B8F

Q30573030-11C0D817-F869-492F-AFF7-FB65B08CB018

Q30573030-1B63632C-30F4-4481-A94A-178C5241A84D

Q30573030-20538B31-ABF7-4D33-A496-A0B949CBAB7C

Q30573030-2A0D06FF-6DAB-4277-9FF4-8ED0B4AE58EC

Q30573030-3CE461CE-5CE5-4027-B341-618FED48F801

Q30573030-45E6C278-2815-4F86-B6C7-D36C1D2C70AD

Q30573030-46DFDD87-7994-4147-9353-F757B891D244

P304

Q30573030-156305A3-5D0B-4AC5-924B-7F7C63F78E4D

P31

Q30573030-FEFFA957-4ECB-41E8-A132-3BCCA1567AE2

P356

Q30573030-3B183E99-A4A6-473B-B704-7C29D71AF78E

P433

Q30573030-5A2D3459-2B80-4735-874F-E23312FBAB90

P478

Q30573030-39ACC57C-FB95-4137-B166-1A20191F3ED6

P50

Q30573030-AFBC4CFF-9D64-459A-85F7-3664DC3F0A81

P577

Q30573030-426291F0-954C-4A00-8907-70C98493C0A5

P698

Q30573030-55898CE9-BE96-4AF0-B3A2-50C89F25EF0B

P932

Q30573030-2538836E-296D-4759-B247-B9F1598D7283

P356

P1433

Annals of Neurology

P1476

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex

@en

P2093

Lin Xu

http://www.w3.org/2001/XMLSchema#string

Ling-Hui Zeng

http://www.w3.org/2001/XMLSchema#string

Michael Wong

http://www.w3.org/2001/XMLSchema#string

P2860

Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling

Time-restricted role for dendritic activation of the mTOR-p70S6K pathway in the induction of late-phase long-term potentiation in the CA1

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation

Epileptogenesis and reduced inward rectifier potassium current in tuberous sclerosis complex-1-deficient astrocytes

The tuberous sclerosis complex

On the incidence of fits and mental retardation in tuberous sclerosis

A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus.

P304

444-453

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.21331

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P50

David H Gutmann

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18389497

http://www.w3.org/2001/XMLSchema#string

P932

3937593

http://www.w3.org/2001/XMLSchema#string